Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 38

    1.

    Requirements for generic anti-epileptic medicines: a regulatory perspective.

    Maliepaard M, Hekster YA, Kappelle A, van Puijenbroek EP, Elferink AJ, Welink J, Gispen-de Wied CC, Lekkerkerker FJ.

    J Neurol. 2009 Jul 15. [Epub ahead of print] No abstract available. PMID: 19603244 [PubMed - as supplied by publisher]Related articlesFree article

    2.

    The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

    Gispen-de Wied CC, Kritsidima M, Elferink AJ.

    J Nutr Health Aging. 2009 Apr;13(4):376-87. Review.PMID: 19300886 [PubMed - indexed for MEDLINE]Related articles

    3.

    Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.

    Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS.

    Int J Neuropsychopharmacol. 2009 Jul;12(6):823-32. Epub 2009 Jan 21.PMID: 19154656 [PubMed - indexed for MEDLINE]Related articles

    4.

    Blunting of the cardiovascular effect of aspirin by ibuprofen: what is the evidence?

    van Westrhenen R, Gispen-de Wied CC, Lekkerkerker JF.

    Clin Pharmacol Ther. 2008 Jun;83(6):812; author reply 812-3. No abstract available. PMID: 18043688 [PubMed - indexed for MEDLINE]Related articles

    5.

    Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder.

    Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE, van Engeland H.

    J Autism Dev Disord. 2006 Oct;36(7):891-9.PMID: 16865550 [PubMed - indexed for MEDLINE]Related articles

    6.

    Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

    Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC.

    Diabetes Care. 2006 Apr;29(4):786-91.PMID: 16567816 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention.

    Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS.

    J Psychopharmacol. 2006 Nov;20(6):789-98. Epub 2006 Feb 14.PMID: 16478755 [PubMed - indexed for MEDLINE]Related articles

    8.

    Antidepressants use in children and adolescents and the risk of suicide.

    Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ, Gispen-de Wied CC, Ruis JR, Elferink AJ, Storosum JG.

    Eur Neuropsychopharmacol. 2006 Feb;16(2):79-83. Epub 2005 Nov 18.PMID: 16298514 [PubMed - indexed for MEDLINE]Related articles

    9.

    Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment.

    Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC.

    Eur Neuropsychopharmacol. 2006 Apr;16(3):187-94. Epub 2005 Nov 2.PMID: 16263247 [PubMed - indexed for MEDLINE]Related articles

    10.

    Immunological characteristics of diabetes in schizophrenia.

    Cohen D, Batstra MR, Gispen-de Wied CC.

    Diabetologia. 2005 Sep;48(9):1941-2. Epub 2005 Jul 29. No abstract available. PMID: 16052326 [PubMed - indexed for MEDLINE]Related articles

    11.

    Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode.

    Storosum JG, Wohlfarth T, Gispen-de Wied CC, Linszen DH, Gersons BP, van Zwieten BJ, van den Brink W.

    Am J Psychiatry. 2005 Apr;162(4):799-802.PMID: 15800158 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human sensory gating.

    Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS.

    J Psychopharmacol. 2004 Sep;18(3):388-94.PMID: 15358983 [PubMed - indexed for MEDLINE]Related articles

    13.

    How real are patients in placebo-controlled studies of acute manic episode?

    Storosum JG, Fouwels A, Gispen-de Wied CC, Wohlfarth T, van Zwieten BJ, van den Brink W.

    Eur Neuropsychopharmacol. 2004 Aug;14(4):319-23.PMID: 15163442 [PubMed - indexed for MEDLINE]Related articles

    14.

    Attenuated stress responsiveness in an animal model for neurodevelopmental psychopathological disorders.

    Terpstra J, Gispen-De Wied CC, Broekhoven MH, Frankhuijzen AC, Kahn RS, van Ree JM, Wiegant VM.

    Eur Neuropsychopharmacol. 2003 Aug;13(4):249-56.PMID: 12888184 [PubMed - indexed for MEDLINE]Related articles

    15.

    [Schizophrenia and diabetes mellitus: not an improbable combination]

    Cohen D, Gispen-de Wied CC.

    Ned Tijdschr Geneeskd. 2003 May 24;147(21):993-6. Dutch. PMID: 12811967 [PubMed - indexed for MEDLINE]Related articles

    16.

    Differentiation between autism and multiple complex developmental disorder in response to psychosocial stress.

    Jansen LM, Gispen-de Wied CC, van der Gaag RJ, van Engeland H.

    Neuropsychopharmacology. 2003 Mar;28(3):582-90. Epub 2002 Aug 6.PMID: 12629541 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol.

    Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS.

    Biol Psychiatry. 2002 Nov 1;52(9):887-95.PMID: 12399142 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia.

    Oranje B, Van Oel CJ, Gispen-De Wied CC, Verbaten MN, Kahn RS.

    J Clin Psychopharmacol. 2002 Aug;22(4):359-65.PMID: 12172334 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia.

    Scheepers FE, Gispen-De Wied CC, Westenberg HG, Kahn RS.

    J Clin Psychopharmacol. 2002 Jun;22(3):333-4. No abstract available. PMID: 12006906 [PubMed - indexed for MEDLINE]Related articles

    20.

    The stress-vulnerability hypothesis in psychotic disorders: focus on the stress response systems.

    Gispen-de Wied CC, Jansen LM.

    Curr Psychiatry Rep. 2002 Jun;4(3):166-70. Review.PMID: 12003677 [PubMed - indexed for MEDLINE]Related articles

    21.

    The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.

    Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS.

    Neuropsychopharmacology. 2001 Oct;25(4):468-75.PMID: 11557160 [PubMed - indexed for MEDLINE]Related articlesFree article

    22.

    Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia.

    Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS.

    Am J Psychiatry. 2001 Apr;158(4):644-6.PMID: 11282704 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    Stress in schizophrenia: an integrative view.

    Gispen-de Wied CC.

    Eur J Pharmacol. 2000 Sep 29;405(1-3):375-84. Review.PMID: 11033342 [PubMed - indexed for MEDLINE]Related articles

    24.

    Commentary on plasma levels of homovanillic acid (phVA) under influence of mental stress.

    Oranje B, Bijl S, Campagne A, Gispen-de Wied CC.

    Neuropsychopharmacology. 2000 Sep;23(3):345-6. No abstract available. PMID: 11032428 [PubMed - indexed for MEDLINE]Related articlesFree article

    25.

    Unresponsiveness to psychosocial stress in a subgroup of autistic-like children, multiple complex developmental disorder.

    Jansen LM, Gispen-de Wied CC, Van der Gaag RJ, ten Hove F, Willemsen-Swinkels SW, Harteveld E, Van Engeland H.

    Psychoneuroendocrinology. 2000 Nov;25(8):753-64.PMID: 10996471 [PubMed - indexed for MEDLINE]Related articles

    26.

    Prenatal exposure to famine and brain morphology in schizophrenia.

    Hulshoff Pol HE, Hoek HW, Susser E, Brown AS, Dingemans A, Schnack HG, van Haren NE, Pereira Ramos LM, Gispen-de Wied CC, Kahn RS.

    Am J Psychiatry. 2000 Jul;157(7):1170-2.PMID: 10873931 [PubMed - indexed for MEDLINE]Related articlesFree article

    27.

    Selective impairments in the stress response in schizophrenic patients.

    Jansen LM, Gispen-de Wied CC, Kahn RS.

    Psychopharmacology (Berl). 2000 Apr;149(3):319-25.PMID: 10823414 [PubMed - indexed for MEDLINE]Related articles

    28.

    Pituitary-adrenal function in adolescent psychiatric patients: impact of depressive symptoms.

    Gispen-de Wied CC, Jansen LM, Duyx JH, Thijssen JH, van Engeland H.

    J Affect Disord. 2000 Jul;59(1):71-6.PMID: 10814774 [PubMed - indexed for MEDLINE]Related articles

    29.

    Psychotic illness after prenatal exposure to the 1953 Dutch Flood Disaster.

    Selten JP, van der Graaf Y, van Duursen R, Gispen-de Wied CC, Kahn RS.

    Schizophr Res. 1999 Feb 15;35(3):243-5.PMID: 10093869 [PubMed - indexed for MEDLINE]Related articles

    30.

    Pituitary-adrenal reactivity in a child psychiatric population: salivary cortisol response to stressors.

    Jansen LM, Gispen-de Wied CC, Jansen MA, van der Gaag RJ, Matthys W, van Engeland H.

    Eur Neuropsychopharmacol. 1999 Jan;9(1-2):67-75.PMID: 10082230 [PubMed - indexed for MEDLINE]Related articles

    31.

    Blunted cortisol response to a psychosocial stressor in schizophrenia.

    Jansen LM, Gispen-de Wied CC, Gademan PJ, De Jonge RC, van der Linden JA, Kahn RS.

    Schizophr Res. 1998 Sep 7;33(1-2):87-94.PMID: 9783348 [PubMed - indexed for MEDLINE]Related articles

    32.

    Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population.

    Gispen-de Wied CC, Jansen LM, Wynne HJ, Matthys W, van der Gaag RJ, Thijssen JH, van Engeland H.

    Psychoneuroendocrinology. 1998 Apr;23(3):295-306.PMID: 9695132 [PubMed - indexed for MEDLINE]Related articles

    33.

    Determination of dexamethasone in saliva.

    Thijssen JH, Gispen-de Wied CC, van Heeswijk GM, Veeman W.

    Clin Chem. 1996 Aug;42(8 Pt 1):1238-42.PMID: 8697583 [PubMed - indexed for MEDLINE]Related articlesFree article

    34.

    Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study.

    Gispen-de Wied CC, Kok FW, Koppeschaar HP, Wynne HJ, Westenberg HG, Thijssen JH, van Ree JM.

    Eur Neuropsychopharmacol. 1993 Dec;3(4):533-41.PMID: 8111227 [PubMed - indexed for MEDLINE]Related articles

    35.

    Inhibition of the pituitary-adrenal axis with dexamethasone and cortisol in depressed patients and healthy subjects: a dose-response study.

    Gispen-de Wied CC, D'Haenen H, Verhoeven WM, Wynne HJ, Westenberg HG, Thijssen JH, Van Ree JM.

    Psychoneuroendocrinology. 1993;18(3):191-204.PMID: 8390700 [PubMed - indexed for MEDLINE]Related articles

    36.

    Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects.

    Gispen-de Wied CC, Westenberg HG, Koppeschaar HP, Thijssen JH, van Ree JM.

    Eur Neuropsychopharmacol. 1992 Dec;2(4):411-9.PMID: 1336998 [PubMed - indexed for MEDLINE]Related articles

    37.

    Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.

    Kahn RS, Westenberg HG, Verhoeven WM, Gispen-de Wied CC, Kamerbeek WD.

    Int Clin Psychopharmacol. 1987 Jan;2(1):33-45.PMID: 3312397 [PubMed - indexed for MEDLINE]Related articles

    38.

    The dexamethasone and cortisol suppression test in depression: beta-endorphin as a useful marker.

    Gispen-de-Wied CC, Westenberg HG, Thijssen JH, van Ree JM.

    Psychoneuroendocrinology. 1987;12(5):355-66.PMID: 2829262 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...